Skip to main content
. 2019 Jun 4;24(9):1174–1179. doi: 10.1634/theoncologist.2019-0189

Table 1. Baseline characteristics of the included trials.

image

*

Rego 80+ is a dose‐escalation strategy with weekly increase in the dosing if no drug‐related side effects up to 160 mg/day.

Abbreviations: BSC, best‐supportive care and placebo; ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression‐free survival; PS, performance status.